 179 monozigoturi da 85 dizigoturi wyvili iqna gamokvleuli F  filtvebis disfunqciasa da sisxlZarRvebis elastiurobis daqveiTebas Soris inaxa mWidro genetikuri urTierTkavSiri  aTerosklerozsa da sasunTqi gzebis daavadebebs aqvT genetikuri korelacia.

 TST- is aqvs axal testebze meti an toli sensitiuroba  T-SPOT -is gamoyenebisas meti pozitiuri Sedegi iqna miRebuli, vidre Quantiferon-TB GOLD- s dros  specifiuroba orive axali testisa gacilebiT maRalia, vidre TST- is  specifiuroba Quantiferon-TB GOLD- isa T-SPOT-TB -is BCG- vaqcinirebul pirebSi erTnairia  Sualeduri(ganusazRvreli) Sedegebi erTnairia  CD4+-is donem ar moaxdina raime gavlena testebis Sedegze (461,29±307,49 )( I. Latorre, X. Martinez-Lacasa, R. Font, A. Lacoma, J. Puig, C. Tural, E. Cuchi, J. Lite, C. Prat, M. Perez, V. Ausina, J. Dominguez (Terrassa, Badalona, Spain )  CD4 + and CD8 + T -ujredebisadmi PPD- s pecifiuroba mcirdeba dabali incidentobis qveynebSi, SedarebiT maRali incidentobis qveynebisa (20% vs 64,1%) (C. Giehl (Saarbrucken, Germany))

 upiratesoba mieniWos mantus tests (TST ) maRali incidentobis qveynebSi  IFG-assay aqtiurad gamoiyenos latenturi DA tuberkulozis diagnostirebisTvis dabali incidentobis qveynebSi

 gama-interferonis producirebuli proteini ( Interferon gamma-induced protein 10 kDa (IP-10). miekuTvneba CXC jgufis citokinebs  sekretirdeba IFN-γ sapasuxod monocitebis, endoTeliaruli ujredebisa da fibroblastebis mier IFN-γ  misi done momatebulia virusuli “C” hepatitis dros  IP-10- is donis 150 pg/mL- ze nakleboba aiv-inficirebul pirebSi arT-Terapiis dawyebamde iTvleba keTilsaimedo niSnad  Kkvlevebma aCvenes, rom IP-10 aseve avlens specifiur pasuxs tuberkulozuri mikobaqteriis mimarT A  aiv-inficirebul pirebSi IP-10 iyo markeri M. tuberculosis –is sapasuxod, damoukideblad CD4+T ujredebis donisa ( D. Goletti, A. Raja, B. Syed Ahamed Kabeer, C. Rodrigues, A. Sodha, O. Butera, S. Carrara, G. Vernet, C. Longuet, S. Tangara, M. Leportier, E. Girardi, P. Lagrange (Roma, Italy; Chennai, Mumbai, India; Lyon, Marcy L'Etoile, Paris, France)

 dafuZnebulia ESAT6/CFP10),

 Seqmnilia seCenovis sax. moskovis samedicino akademiis molekuluri medicinis samecniero-kvleviT institutSi  gavlili aqvs aprobacia moskovis, sanqt-peterburgis, samaris da riazanis tub. dawesebulebebSi

 axasiaTebs usafrTxoebis maRali profili  maRali specifiuroba % (p<0,05)  maRali mgrZnobeloba % (p<0,05)  hiperergiuli reaqcia (vezikulut-nekrotuli forma, limfangiti, limfangoiti) % (p<0,05)  mniSvnelovani imunosupresiis dros testi SeiZleba iyos uaryofiTi  saSualebas iZleva vimsjeloT procesis aqtivobaze da SevafasoT antituberkulozuri Terepiis efeqturoba (gankurnebulebSi testi uaryofiTia)

 gacilebiT iafia  ar saWiroebs maRalteqnologiebs (ELISA, T- SPOT)  ar saWiroebs maRalkvalificiur laboratoriul personals